Related Party Transactions

9 Months Ended

Sep. 30, 2015

Related Party Transactions [Abstract]

Related Party Transactions

14. Related Party Transactions

Roche Holdings, Inc. and its affiliates

Revenue from Roche was $4,446,000 and $8,595,000 in the three and nine months ended September 30, 2015, respectively, which consisted of payments made for the reserved capacity arrangement and access to the Company’s molecular information platform under the R&D Collaboration Agreement. Roche-related revenue represented 17.5% and 12.8% of the Company’s total revenue in the three and nine months ended September 30, 2015, respectively. Costs of related party revenue from Roche were $1,302,000 for the three and nine months ended September 30, 2015, which consisted of costs incurred under the molecular information platform program within the R&D Collaboration Agreement.

Revenue from Roche was $164,000 and $684,000 in the three and nine months ended September 30, 2014, respectively, under a previous contractual relationship between Roche and the Company. Roche-related revenue represented 1.0% and 1.6% of the Company’s total revenue in the three and nine months ended September 30, 2014, respectively.

There were no other material Roche-related transactions in the three and nine months ended September 30, 2015 and 2014.

Other related party transactions

The Company recognized revenue of $1,057,000 and $2,369,000 during the three and nine months ended September 30, 2015, respectively, and $272,000 and $402,500 during the three and nine months ended September 2014, respectively, from an arrangement with an entity affiliated with a member of the Board of Directors executed in the year ended December 31, 2013. Of these amounts, $1,090,500 and $419,000 were included in accounts receivable at September 30, 2015 and December 31, 2014, respectively.